Evidence map›Paper›PMID 30076308›Full record

ArticleNature communications2018

A widespread alternate form of cap-dependent mRNA translation initiation.

Columba de la Parra, Amanda Ernlund, Amandine Alard, Kelly Ruggles, Beatrix Ueberheide, Robert J Schneider

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 176 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Circadian Control of Protein Synthesis.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025
    Review
  17. Article
  18. Review
  19. Article
  20. Review

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Columba de la ParraDepartment of Microbiology, NYU School of Medicine, New York, NY, 10016, USA.
Amanda ErnlundDepartment of Microbiology, NYU School of Medicine, New York, NY, 10016, USA.
Amandine AlardDepartment of Microbiology, NYU School of Medicine, New York, NY, 10016, USA.
Kelly RugglesDepartment of Medicine, NYU School of Medicine, New York, NY, 10016, USA.ORCID http://orcid.org/0000-0002-0152-0863
Beatrix UeberheideDepartment of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY, 10016, USA.
Robert J SchneiderDepartment of Microbiology, NYU School of Medicine, New York, NY, 10016, USA. robert.schneider@nyumc.org.ORCID http://orcid.org/0000-0001-5807-5564
New York University · USNYU Langone’s Laura and Isaac Perlmutter Cancer Center

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
TRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3M
the mTOR translational control pathway in tamoxifen resistant ER+ breast cancerR01CA207893 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHNEIDER, ROBERT JAY · 2017 to 2021
$2.1M
Translational regulation of the breast cancer stem cell by eIF4G1R01CA178509 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHNEIDER, ROBERT JAY · 2015 to 2019
$2.0M
American Cancer Society (American Cancer Society, Inc.) ACS PF-16-095-01-RMCBreast Cancer Research Foundation (BCRF) BCRF-16-143NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA178509NCI NIH HHS R01 CA207893NCI NIH HHS T32 CA009161U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30CA016087U.S. Department of Health & Human Services | National Institutes of Health (NIH) RO1CA178509U.S. Department of Health & Human Services | National Institutes of Health (NIH) RO1CA207893U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32 CA009161
6 · The paper itself

Abstract

Translation initiation of most mammalian mRNAs is mediated by a 5' cap structure that binds eukaryotic initiation factor 4E (eIF4E). However, inactivation of eIF4E does not impair translation of many capped mRNAs, suggesting an unknown alternate mechanism may exist for cap-dependent but eIF4E-independent translation. We show that DAP5, an eIF4GI homolog that lacks eIF4E binding, utilizes eIF3d to facilitate cap-dependent translation of approximately 20% of mRNAs. Genome-wide transcriptomic and translatomic analyses indicate that DAP5 is required for translation of many transcription factors and receptor capped mRNAs and their mRNA targets involved in cell survival, motility, DNA repair and translation initiation, among other mRNAs. Mass spectrometry and crosslinking studies demonstrate that eIF3d is a direct binding partner of DAP5. In vitro translation and ribosome complex studies demonstrate that DAP5 and eIF3d are both essential for eIF4E-independent capped-mRNA translation. These studies disclose a widespread and previously unknown mechanism for cap-dependent mRNA translation by DAP5-eIF3d complexes.

Indexed as

Protein BindingAnimalsCell LineEukaryotic Initiation Factor-3Eukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GGene SilencingHEK293 CellsHumansPeptide Chain Initiation, TranslationalProtein Processing, Post-TranslationalRibosomesRNA CapsRNA, MessengerTranscriptomeEIF4G2 protein, humanEukaryotic Initiation Factor-3Eukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GRNA CapsRNA, Messenger

Identifiers

PMID30076308
PMCPMC6076257
OpenAlexW2886137594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.